Ilias Goranitis

Determining the value of genomics in healthcare - Nature Medicine Assessing the value of genomics is key to informing evidence-based policies; this Review outlines how current approaches to health technology assessment, implementation and data management can be adapted to suit the rapidly evolving technology and evidence base.

How can we measure the value of #genomics in #healthcare? How can #HTA, #implementation & data management be adapted to suit the rapidly evolving nature of genomics? For insights, read the Review from Zornitza Stark, Ilias Goranitis & colleagues.
https://www.nature.com/articles/s41591-025-04061-3

We discuss progress in measuring and valuing genomics, evidentiary and process challenges for HTA and practical solutions for policy decisions-making, implementing genomics to deliver value, life-cycle HTA and learning healthcare, broader macro-economic benefits.

Determining the value of genomics in healthcare - Nature Medicine Assessing the value of genomics is key to informing evidence-based policies; this Review outlines how current approaches to health technology assessment, implementation and data management can be adap...

In this Nature Medicine paper, we draw from our experiences in evaluating and implementing #genomics in Australia, Canada, England, Hong Kong and the US

www.nature.com/articles/s41...

Determining the value of genomics in healthcare” is now published in Nature Medicine. Led by A/Prof Ilias Goranitis, the paper brings together international co-authors to examine how the value of genomics can be assessed.
Read the full article: www.nature.com/articles/s41...

www.nature.com/articles/s41...

🔥🔥🔥 Is genomics value for money??? 🧬💰

👉 How do we define it?
👉 Measure it?
👉 And deliver it?

rdcu.be/eR243

@iliasgoranitis.bsky.social @stephaniebest.bsky.social @hadleyssmith.bsky.social @rich-genomics.bsky.social @jbuchanan-ox.bsky.social @rdexeter.bsky.social

Feasibility, acceptability and clinical outcomes of the BabyScreen+ genomic newborn screening study - Nature Medicine The BabyScreen+ study offered genomic screening to 1,000 newborns in Australia, and showed that the approach is feasible and positively received by families, leading to molecular diagnoses in 1.6% of babies.

Proud to share our BabyScreen+ #gNBS study is now out in @naturemedicine.bsky.social: 1000 babies screened, results in <2wks, 16 high chance findings, incl. 2 with major impact on care. Big thanks to @zornitza.bsky.social and the study team!

www.nature.com/articles/s41...

🤗 Out now @naturemedicine.bsky.social results of our genomic NBS study BabyScreen+ 👶🧬

👉 www.nature.com/articles/s41...

1,000 babies
WGS using existing cards
600+ conditions
13 day TAT
16 diagnoses (vs 1 in std NBS)
High clinical impact
High parental acceptability

Health care financing and the sustainability of health systems - PubMed The economic crisis brought an unprecedented attention to the issue of health system sustainability in the developed world. The discussion, however, has been mainly limited to "traditional" issues of ...

The sustainability argument is a strong one in favour of tax-based systems — read our commentary pubmed.ncbi.nlm.nih.gov/26369417/

Help us develop a roadmap for stakeholders to consider when integrating #healtheconomics alongside #genomics to inform decision-making. Please share your local perspectives on challenges & opportunities of evaluating and implementing genomics
q.surveys.unimelb.edu.au/jfe/form/SV_...

Wonderful to see our paper on the #Value and #Implementation of #Genomic_Newborn_Screening published in @ajhgnews.bsky.social #BabyScreen+ #HealthEconomics #DCE

Public preferences for the value and implementation of genomic newborn screening: Insights from two discrete choice experiments in Australia Integrating genomic sequencing into newborn screening (NBS) has transformative potential for the identification and management of genetic conditions. …

What does the Australian public think about the value and implementation of genomic NBS? 🧬👶⚖️

@ajhgnews.bsky.social

@iliasgoranitis.bsky.social @stephaniebest.bsky.social @genomeseb.bsky.social @genetic-fi.bsky.social

#raredisease #genomics #healtheconomics

www.sciencedirect.com/science/arti...

Genomics in public health: Technology assessment YouTube video by PAHO TV

A few weeks ago, @iliasgoranitis.bsky.social
presented at the Pan American Health Organisation webinar series. The webinar explored the challenges and opportunities of incorporating genomic innovations into health systems. youtube.com/watch?v=cPQr...

The Cost Effectiveness of Genomic Medicine in Cancer Control: A Systematic Literature Review - Applied Health Economics and Health Policy Background and Objective Genomic medicine offers an unprecedented opportunity to improve cancer outcomes through prevention, early detection and precision therapy. Health policy makers worldwide are d...

A must-read:
The Cost-Effectiveness of #Genomic_Medicine in #Cancer Control: A Systematic Literature Review

link.springer.com/article/10.1...

Grateful to the @who.int and Cancer Australia for their support.

Using implementation science to navigate the complexity of integrating genomics into healthcare Nature Medicine - Australian Genomics led a country-level, longitudinal project to deliver and evaluate the impact of genomics in routine healthcare.

As @ausgenomics.bsky.social comes to an end: what have we learned? 🇦🇺🧬 @naturemedicine.bsky.social
👉 rdcu.be/eeuAN
Change is hard! Key for success: working across disciplines; jurisdictions; and all leadership levels🏆
@stephaniebest.bsky.social @iliasgoranitis.bsky.social @andrewmallett8.bsky.social

(1/4) Attention Early Career Researchers (ECRs)! We are still collecting expressions of interest for our ECR ‘Preprint Club’ series for 2025. #IHEA #healtheconomics #genomics #precisionmedicine

Utilisation of subsidised genetic and genomic testing in a publicly funded healthcare system 2014–2023 European Journal of Human Genetics - Utilisation of subsidised genetic and genomic testing in a publicly funded healthcare system 2014–2023

What happens when #genomic testing is funded?🧬

👉 rdcu.be/d8MSL

Last 10yrs 🇦🇺:
Many tests approved as evidence grows ✅
BUT testing volumes low AND inequitable access
Budget impact of #genomics minor: AU$3Mpa or <0.01% of all health expenditure 💰

@ausgenomics.bsky.social @iliasgoranitis.bsky.social

Utilisation of subsidised genetic and genomic testing in a publicly funded healthcare system 2014–2023 - European Journal of Human Genetics European Journal of Human Genetics - Utilisation of subsidised genetic and genomic testing in a publicly funded healthcare system 2014–2023

New paper in the European Journal of Human Genetics:

Utilisation of subsidised genetic and genomic testing in Australia during 2014–2023

www.nature.com/articles/s41...

@CancerAustralia has now launched the National Framework for Genomics in Cancer Control. www.canceraustralia.gov.au/key-initiati...

It was an honor to lead the #healtheconomics component of the evidence review that informed the development of this framework. Access it through link ⬇️

A Standardized Measurement and Valuation Scale of Genomic Utility for Policy Decisions: The GUV Scale The multifaceted ways in which genomics can be valuable to clinicians, patients, families, and society are important for informing prioritization decisions by policy makers. This study aims to develop...

How do we measure the value of #genomics for #policy decisions? Check out our new GUV scale!

👉 www.valueinhealthjournal.com/article/S109...

👏 great collaboration @iliasgoranitis.bsky.social @andrewmallett8.bsky.social @stephaniebest.bsky.social @zoefehlberg.bsky.social @ausgenomics.bsky.social

We further map genomic utility evidence from different publicly funded rare disease genomic tests in Australia onto the GUV scale to indicate acceptable #thresholds of #genomic_utility to support prioritization decisions.
Read more here doi.org/10.1016/j.jv...

How the GUV scale can be used to support policy decisions is illustrated through a stylized example.

The scale can be used
by researchers in rare disease genomics to design evaluations that capture the key outcomes of genomics &
by health technology assessment (HTA) bodies to support policy decisions based on standardized and quantifiable evidence of genomic utility.

Using @1OOOminds, we performed a multicriteria decision analysis #MCDA with experts involved in policy, clinical, research, and consumer advocacy leadership to enable the cumulative and preference-based scoring of genomic utility on a 0 to 100 scale.

Our work, published in #ValueinHealth @ISPORJournals, now enables consistency in reporting and benchmarking of different genomic test indications, facilitating evidence-based research and policy decisions.

GUV-scale
New way to measure & score genomic utility on a 0-100% scale based on 5 policy priority indicators (clinical, diagnostic, economic, societal, and family utility)

doi.org/10.1016/j.jv...

@zornitza.bsky.social @stephaniebest.bsky.social @andrewmallett8.bsky.social @ausgenomics.bsky.social

Details : Research Assistant / Research Fellow, Health Economics : The University of Melbourne Careers at The University of Melbourne

New role within our Economics of Genomics & Precision Medicine Unit - Applications deadline Jan 20 #healtheconomics

jobs.unimelb.edu.au/caw/en/job/9...

Testament to the quality of the work we did with Australian Genomics and the hard work of everyone in my Economics of Genomics and Precision Medicine Unit and Australian Genomics teams!

Honoured to receive a Dame Kate Campbell Fellowship and join excellent colleagues in the Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne who have inspired me with their work over the years!

Drinking coffee now from my not so secret Santa gift

An important step towards the economic evaluation of #FunctionalGenomics! A #MicroCosting of mass-spectrometry based quantitative #Proteomics url.au.m.mimecastprotect.com/s/TeIxCxnMJ5... @ausgenomics.bsky.social